Literature DB >> 30560367

A simple approach for restoration of differentiation and function in cryopreserved human hepatocytes.

Magnus Ölander1, Jacek R Wiśniewski2, Inken Flörkemeier1, Niklas Handin1, Jozef Urdzik3, Per Artursson4.   

Abstract

Primary human hepatocytes are used in all facets of liver research, from in vitro studies of xenobiotic disposition and toxicity to the clinical management of liver failure. Unfortunately, cellular stress during isolation and cryopreservation causes a highly unpredictable loss of the ability to attach and form cell-matrix and cell-cell interactions. Reasoning that this problem could be mitigated at the post-thawing stage, we applied label-free quantitative global proteomics to analyze differences between attached and non-attached fractions of cryopreserved human hepatocyte batches. Hepatocytes that were unable to attach to a collagen matrix showed many signs of cellular stress, including a glycolytic phenotype and activation of the heat shock response, ultimately leading to apoptosis activation. Further analysis of the activated stress pathways revealed an increase in early apoptosis immediately post-thawing, which suggested the possibility of stress reversal. Therefore, we transiently treated the cells with compounds aimed at decreasing cellular stress via different mechanisms. Brief exposure to the pan-caspase apoptosis inhibitor Z-VAD-FMK restored attachment ability and promoted a differentiated morphology, as well as formation of 3D spheroids. Further, Z-VAD-FMK treatment restored metabolic and transport functions, with maintained sensitivity to hepatotoxic insults. Altogether, this study shows that differentiation and function of suboptimal human hepatocytes can be restored after cryopreservation, thus markedly increasing the availability of these precious cells.

Entities:  

Keywords:  Apoptosis; Cellular stress; Cryopreservation; Hepatotoxicity; Human hepatocytes; Proteomics

Mesh:

Substances:

Year:  2018        PMID: 30560367     DOI: 10.1007/s00204-018-2375-9

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  7 in total

1.  Toward a Consensus on Applying Quantitative Liquid Chromatography-Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper.

Authors:  Bhagwat Prasad; Brahim Achour; Per Artursson; Cornelis E C A Hop; Yurong Lai; Philip C Smith; Jill Barber; Jacek R Wisniewski; Daniel Spellman; Yasuo Uchida; Michael A Zientek; Jashvant D Unadkat; Amin Rostami-Hodjegan
Journal:  Clin Pharmacol Ther       Date:  2019-07-26       Impact factor: 6.875

Review 2.  Chemical approaches to cryopreservation.

Authors:  Kathryn A Murray; Matthew I Gibson
Journal:  Nat Rev Chem       Date:  2022-07-18       Impact factor: 34.571

3.  Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes.

Authors:  Christine Wegler; Pär Matsson; Veronica Krogstad; Jozef Urdzik; Hege Christensen; Tommy B Andersson; Per Artursson
Journal:  Mol Pharm       Date:  2021-03-19       Impact factor: 4.939

4.  Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer.

Authors:  Inken Flörkemeier; Tamara N Steinhauer; Nina Hedemann; Magnus Ölander; Per Artursson; Bernd Clement; Dirk O Bauerschlag
Journal:  Ther Adv Med Oncol       Date:  2021-11-25       Impact factor: 8.168

5.  Hepatic Models in Precision Medicine: An African Perspective on Pharmacovigilance.

Authors:  Tracey Hurrell; Jerolen Naidoo; Janine Scholefield
Journal:  Front Genet       Date:  2022-04-14       Impact factor: 4.772

6.  Characterization of Human Induced Pluripotent Stem Cell-Derived Hepatocytes with Mature Features and Potential for Modeling Metabolic Diseases.

Authors:  Gustav Holmgren; Benjamin Ulfenborg; Annika Asplund; Karin Toet; Christian X Andersson; Ann Hammarstedt; Roeland Hanemaaijer; Barbara Küppers-Munther; Jane Synnergren
Journal:  Int J Mol Sci       Date:  2020-01-11       Impact factor: 5.923

7.  PSD3 downregulation confers protection against fatty liver disease.

Authors:  Rosellina M Mancina; Kavitha Sasidharan; Anna Lindblom; Ying Wei; Ester Ciociola; Oveis Jamialahmadi; Piero Pingitore; Anne-Christine Andréasson; Giovanni Pellegrini; Guido Baselli; Ville Männistö; Jussi Pihlajamäki; Vesa Kärjä; Stefania Grimaudo; Ilaria Marini; Marco Maggioni; Barbara Becattini; Federica Tavaglione; Carly Dix; Marie Castaldo; Stephanie Klein; Mark Perelis; Francois Pattou; Dorothée Thuillier; Violeta Raverdy; Paola Dongiovanni; Anna Ludovica Fracanzani; Felix Stickel; Jochen Hampe; Stephan Buch; Panu K Luukkonen; Daniele Prati; Hannele Yki-Järvinen; Salvatore Petta; Chao Xing; Clemens Schafmayer; Elmar Aigner; Christian Datz; Richard G Lee; Luca Valenti; Daniel Lindén; Stefano Romeo
Journal:  Nat Metab       Date:  2022-01-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.